Keyphrases
Natalizumab
100%
Progressive multifocal Leukoencephalopathy
100%
Multiple Sclerosis
100%
Immune Reconstitution
18%
Plasma Exchange
18%
JC Virus
18%
Seizure
9%
Improved Outcomes
9%
Contrast Enhancement
9%
Treatment Duration
9%
Clinical Events
9%
Multiple Sclerosis Treatment
9%
Disease-modifying Therapy
9%
Clinical Diagnosis
9%
Symptom Onset
9%
HIV-associated
9%
Future Therapeutics
9%
Enlargement
9%
Predictive Marker
9%
Patients at Risk
9%
Motor Performance
9%
Exposure Time
9%
Presenting Symptoms
9%
Rare Occurrence
9%
PCR Test
9%
Cognition Performance
9%
Neuroscience
Natalizumab
100%
Progressive Multifocal Leukoencephalopathy
100%
Multiple Sclerosis
100%
Magnetic Resonance Imaging
27%
JC Virus
18%
Blood Plasma
18%
Immunosuppressant
9%
Human Immunodeficiency Virus
9%
Treatment of Multiple Sclerosis
9%
Vigilance
9%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Sclerosis
100%
Natalizumab
100%
Progressive Multifocal Leukoencephalopathy
100%
JC Virus
18%
Immune Reconstitution Inflammatory Syndrome
18%
Immunosuppressive Agent
9%
HIV
9%
Syndrome
9%
Diseases
9%